Recomendation Reports

569

2020/October

Natalizumab

Natalizumab for the treatment of relapsing-remitting multiple sclerosis after the first treatment failure

564

2020/October

Naproxen

Expansion of the use of naproxen for the treatment of reactive arthritis

561

2020/September

Ocrelizumab

Ocrelizumab for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) as an alternative or when there is a contraindication to natalizumab

560

2020/September

Dabigatran etexilate and idarucizumab

Dabigatran for prevention of stroke in patients over 60 years with non-valvular atrial fibrillation who are unable to remain in the therapeutic range of international normalized ratio with warfarin and idarucizumab for reversing the anticoagulant effect of dabigatran

559

2020/September

Bortezomib

Bortezomib for the treatment of adult patients with previously untreated multiple myeloma who are ineligible for autologous haematopoietic stem cell transplantation

558

2020/September

Bortezomib

Bortezomib for the treatment of adult patients with previously untreated multiple myeloma who are eligible for autologous haematopoietic stem cell transplantation

557

2020/September

Bortezomib

Bortezomib for the treatment of adult patients with previously treated multiple myeloma

552

2020/August

Risedronate 5mg tablets

Exclusion of risedronate 5mg for the treatment of patients with Paget’s disease

549

2020/August

Ranibizumab

Ranibizumab for the treatment of diabetic macular edema (DME)

548

2020/August

Automated liquid culture for detection of mycobacteria and susceptibility testing to antimicrobials used in the treatment of tuberculosis

Automated liquid culture for detection of mycobacteria and susceptibility testing to antimicrobials used in the treatment of tuberculosis

547

2020/August

Delamanid (Deltyba®)

Delamanid for the treatment of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis

546

2020/August

Bedaquiline (Sirturo®)

Bedaquiline for patients with rifampicin-resistant, multidrug-resistant and extensively drug-resistant tuberculosis

545

2020/August

Universal testing for hepatitis C in pregnant women in the first trimester of pregnancy during antenatal care

Universal testing for hepatitis C in pregnant women in antenatal care

544

2020/August

Levothyroxine sodium

Inclusion of levothyroxine sodium presentations of 12.5 and 37.5 mcg for treatment of congenital hypothyroidism

541

2020/June

Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies(ipilimumab, nivolumab, pembrolizumab)

Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma

540

2020/July

Vestronidase alfa (Mepsevii®)

Vestronidase alfa for the treatment of mucopolysaccharidosis type VII

539

2020/June

Sirolimus

Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis

538

2020/June

Tofacitinib Citrate (Xeljanz®)

Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs

537

2020/July

Tofacitinib Citrate (Xeljanz®)

Tofacitinib citrate for the treatment of moderate to severe active psoriatic arthritis in adult patients with intolerance or treatment failure with synthetic or biological disease-modifying antirheumatic drugs (DMARDs)

536

2020/August

Ixekizumab (Taltz®)

Ixekizumab for the treatment of active psoriatic arthritis in adult patients with an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs)

535

2020/August

Ixekizumab

Ixekizumab for the treatment of adult patients with moderate to severe psoriasis with treatment failure, contraindication or intolerance to adalimumab

534

2020/September

Risankizumab (SKYRIZI®)

Risankizumab for the treatment of adult patients with moderate to severe plaque psoriasis

533

2020/June

Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)

Increasing the upper age limit to 75 years for allogeneic Haematopoietic Stem Cell Transplantation (HSCT) procedures

532

2020/June

Human anti-hepatitis B immunoglobulin

Human anti-hepatitis B immunoglobulin 1,000 IU

531

2020/June

Ruxolitinib (Jakavi®)

Ruxolitinib for the treatment of patients with primary myelofibrosis, postpolycythaemia vera myelofibrosis or postessential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease

526

2020/June

Rifapentine plus isoniazid (3HP regimen)

Rifapentine plus isoniazid for treatment of Latent Mycobacterium Tuberculosis Infection (LTBI)

525

2020/June

Rifampicin 300 mg capsule, and 20 mg/mL oral suspension

Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease

524

2020/March

Empagliflozin and Dapagliflozin

Empagliflozin and Dapagliflozin for the treatment of Type 2 Diabetes Mellitus

523

2020/March

Orlistat

Orlistat for weight loss in overweight or obese patients

522

2020/March

Sibutramine

Sibutramine for the treatment of obese patients

519

2020/March

Riociguat

Riociguat for inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension

518

2020/April

Treatment of Pseudomyxoma Peritonei

Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

517

2020/April

Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy(HIPEC)

Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma

516

2020/March

Newborn Screening

Newborn Screening for Congenital Toxoplasmosis

515

2020/March

Dolutegravir

Dolutegravir for the treatment of pregnant women living with HIV

510

2020/March

Baricitinib (Olumiant®)

Baricitinib (Olumiant®) for patients with moderate to severe Active Rheumatoid Arthritis

509

2020/March

Mirabegron

Mirabegron for the treatment of storage dysfunction in patients with Neurogenic Bladder

508

2020/March

Oxybutynin, Tolterodine, Solifenacin and Darifenacin

Antimuscarinics (Oxybutynin, Tolterodine, Solifenacin and Darifenacin) for the treatment of Storage Dysfunction in patients with Neurogenic Bladder

507

2020/March

Photodynamic Therapy

Photodynamic Therapy for non-melanoma skin cancer

506

2020/February

Personal Frequency Modulation System

Personal frequency modulation system for hearing-impaired students at any age and at any academic level

503

2020/January

Testing for prothrombin gene mutation (G202110A), protein C functional assay, protein S functional assay, anti-beta2-glycoprotein I - IgG, lupus anticoagulant

Diagnostic tests for thrombophilia in pregnancy

501

2019/November

Pyrazinamide 150 mg dispersible tablets

Incorporation of pyrazinamide 150 mg dispersible tablets in the Brazilian National Relation of Essential Medicines (RENAME in Portuguese)